Breaking barriers: the latest insights into KRAS G12C inhibitors.
作者信息
Attieh Fouad, Kourie Hampig Raphaël
机构信息
Faculty of Medicine, Saint Joseph University of Beirut, Beirut, 11072180, Lebanon.
Department of Hematology-Oncology, Faculty of Medicine, Saint Joseph University of Beirut, Beirut, 11072180, Lebanon.
出版信息
Future Oncol. 2024;20(35):2685-2688. doi: 10.1080/14796694.2024.2394009. Epub 2024 Sep 12.
Abstract
摘要
相似文献
1
Breaking barriers: the latest insights into KRAS G12C inhibitors.
Future Oncol. 2024;20(35):2685-2688. doi: 10.1080/14796694.2024.2394009. Epub 2024 Sep 12.
2
Activity and resistance to KRAS inhibitors in non-small cell lung cancer and colorectal cancer.
Biochim Biophys Acta Rev Cancer. 2024 May;1879(3):189108. doi: 10.1016/j.bbcan.2024.189108. Epub 2024 May 8.
3
An updated overview of K-RAS G12C inhibitors in advanced stage non-small cell lung cancer.
Future Oncol. 2024;20(37):3019-3038. doi: 10.1080/14796694.2024.2407280. Epub 2024 Oct 3.
4
Differential Response and Resistance to KRAS-Targeted Therapy.
Mol Carcinog. 2025 Jul;64(7):1135-1148. doi: 10.1002/mc.23908. Epub 2025 Apr 21.
5
Literature review of advances and challenges in mutant non-small cell lung cancer.
Transl Lung Cancer Res. 2025 Jul 31;14(7):2799-2820. doi: 10.21037/tlcr-2025-164. Epub 2025 Jul 15.
6
Current status of KRAS G12C inhibitors in NSCLC and the potential for combination with anti-PD-(L)1 therapy: a systematic review.
Front Immunol. 2025 Apr 15;16:1509173. doi: 10.3389/fimmu.2025.1509173. eCollection 2025.
7
Sotorasib: a treatment for non-small cell lung cancer with the KRAS G12C mutation.
Drugs Today (Barc). 2022 Apr;58(4):175-185. doi: 10.1358/dot.2022.58.4.3400573.
8
KRAS-mutant non-small cell lung cancer (NSCLC) therapy based on tepotinib and omeprazole combination.
Cell Commun Signal. 2024 Jun 12;22(1):324. doi: 10.1186/s12964-024-01667-x.
9
AXL signal mediates adaptive resistance to KRAS G12C inhibitors in KRAS G12C-mutant tumor cells.
Cancer Lett. 2024 Apr 10;587:216692. doi: 10.1016/j.canlet.2024.216692. Epub 2024 Feb 9.
10
The FGFR inhibitor pemigatinib overcomes cancer drug resistance to KRAS G12C inhibitors in mesenchymal lung cancer.
PLoS One. 2025 Aug 11;20(8):e0327588. doi: 10.1371/journal.pone.0327588. eCollection 2025.
引用本文的文献
1
Network pharmacology and AI in cancer research uncovering biomarkers and therapeutic targets for RALGDS mutations.
Sci Rep. 2025 Mar 29;15(1):10938. doi: 10.1038/s41598-025-91568-x.
本文引用的文献
1
From bench to bedside: current development and emerging trend of KRAS-targeted therapy.
Acta Pharmacol Sin. 2024 Apr;45(4):686-703. doi: 10.1038/s41401-023-01194-4. Epub 2023 Dec 4.
2
Osimertinib with or without Chemotherapy in -Mutated Advanced NSCLC.
N Engl J Med. 2023 Nov 23;389(21):1935-1948. doi: 10.1056/NEJMoa2306434. Epub 2023 Nov 8.
3
Sotorasib plus Panitumumab in Refractory Colorectal Cancer with Mutated G12C.
N Engl J Med. 2023 Dec 7;389(23):2125-2139. doi: 10.1056/NEJMoa2308795. Epub 2023 Oct 22.
4
KRAS-independent feedback activation of wild-type RAS constrains KRAS inhibitor efficacy.
Cell Rep. 2022 Jun 21;39(12):110993. doi: 10.1016/j.celrep.2022.110993.
5
KRAS mutation: from undruggable to druggable in cancer.
Signal Transduct Target Ther. 2021 Nov 15;6(1):386. doi: 10.1038/s41392-021-00780-4.
6
EGFR Blockade Reverts Resistance to KRAS Inhibition in Colorectal Cancer.
Cancer Discov. 2020 Aug;10(8):1129-1139. doi: 10.1158/2159-8290.CD-20-0187. Epub 2020 May 19.
7
K-Ras(G12C) inhibitors allosterically control GTP affinity and effector interactions.
Nature. 2013 Nov 28;503(7477):548-51. doi: 10.1038/nature12796. Epub 2013 Nov 20.
Zotero 插件